Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne Jerry Tan, MD, Diane Thiboutot, MD, Georg Popp,

Slides:

Advertisements

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Advertisements

A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold.

A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Analysis of US dermatology physician assistant density

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

Analysis of US dermatology physician assistant density

Facial adenocarcinoma treated with intra-arterial chemotherapy

A randomized controlled crossover trial: Lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle Kathryn.

The impact of chocolate consumption on acne vulgaris in college students: A randomized crossover study Gregory R. Delost, DO, Maria E. Delost, PhD, Jenifer.

Efficacy of the long-pulsed 1064-nm neodymium:yttrium-aluminum-garnet laser (LPND) (rejuvenation mode) in the treatment of papulopustular rosacea (PPR):

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Guidelines of care for the management of acne vulgaris

Ahmad Al Aboud, MD, Melissa Abrams, MD, Anthony J. Mancini, MD

Efficacy of simvastatin in plaque psoriasis: A pilot study

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Sarah Sung, MD, Alexa B. Kimball, MD, MPH

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB.

Brad A. Yentzer, MD, Ali Alikhan, BS, Hoa Teuschler, MS, Lisa L

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection Alberto Conde-Taboada, MD, Javier Pedraz Muñoz, MD, Lucía.

Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale Vanessa Lindsay Pascoe, MD, Alexandra Boer.

A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies Linda.

Google search trends for tanning salons: Temporal patterns indicate peak interest in mid spring Derek D. Reed, PhD, BCBA-D Journal of the American Academy.

Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open- label extension study with optional narrow-band ultraviolet.

Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Socioeconomic and geographic barriers to dermatology care in urban and rural US populations Toral Vaidya, MPH, Lindsey Zubritsky, MD, Ali Alikhan, MD,

Lip edema Journal of the American Academy of Dermatology

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis Kenneth B. Gordon, Richard G. Langley,

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis.

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants Roland Kaufmann, MD, Regina Fölster-Holst, MD, Peter Höger, MD,

A comparison of postprocedural wound care treatments: Do antibiotic-based ointments improve outcomes? Zoe D. Draelos, MD, FAAD, Ronald L. Rizer, PhD,

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3.

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Yu-Chen Huang, MD, Ying-Chih Cheng, MD

Modification of the nail psoriasis severity index

Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled.

Tofacitinib therapy for children with severe alopecia areata

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial Boni E. Elewski, MD, Martin.

Postprocedural wound-healing efficacy following removal of dermatosis papulosa nigra lesions in an African American population: A comparison of a skin.

Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Eyebrow transplantation: Alternative body sites as a donor source

Gaps in pain management in dermatology: A needs assessment from Canada

Alan Menter, MD, Stephen K

Efficacy and safety of oxymetazoline cream 1

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

“Boot foot” with pseudomonas colonization

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment Michael.

Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed Grace Kimmel, MD, Margot.

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Adapalene gel 0.3% for the treatment of acne vulgaris: A multicenter, randomized, double-blind, controlled, phase III trial Diane Thiboutot, MD, David.

Presentation transcript:

Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne Jerry Tan, MD, Diane Thiboutot, MD, Georg Popp, MD, Melinda Gooderham, MD, Charles Lynde, MD, James Del Rosso, DO, Jonathan Weiss, MD, Ulrike Blume-Peytavi, MD, Jolanta Weglovska, MD, Sandra Johnson, MD, Lawrence Parish, MD, Dagmara Witkowska, MD, Nestor Sanchez Colon, MD, Alessandra Alió Saenz, MD, Faiz Ahmad, MS, Michael Graeber, MD, Linda Stein Gold, MD Journal of the American Academy of Dermatology Volume 80, Issue 6, Pages 1691-1699 (June 2019) DOI: 10.1016/j.jaad.2019.02.044 Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Facial acne vulgaris: coprimary end point from baseline to week 12. Success according to the facial Investigator's Global Assessment (IGA) is defined as clear or almost clear and at least a 2-grade improvement (intent-to-treat population; multiple imputation [MI]). Journal of the American Academy of Dermatology 2019 80, 1691-1699DOI: (10.1016/j.jaad.2019.02.044) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Truncal acne vulgaris: secondary end points from baseline to week 12. Success rate according to the Physician's Global Assessment (PGA) of truncal acne is defined as a PGA score of 0 or 1 and at least a 2-grade improvement. (intent-to-treat trunk population; multiple imputation [MI]). Journal of the American Academy of Dermatology 2019 80, 1691-1699DOI: (10.1016/j.jaad.2019.02.044) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

Fig 3 Tolerability profile of trifarotene and vehicle from baseline to week 12 in facial and truncal acne. Severity scale score indicates: 0 (none), 1 (mild), 2 (moderate) and 3 (severe). Journal of the American Academy of Dermatology 2019 80, 1691-1699DOI: (10.1016/j.jaad.2019.02.044) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions